Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

February 20, 2027

Conditions

Vasomotor Symptoms

Interventions

DRUG

Asimadoline

Asimadoline TP0052 2.5 mg two (2) tablets bid (two on awakening and two before bed), total of four (4) tablets daily (10 mg) for 8 weeks.

Trial Locations (1)

RECRUITING

Department of Gynecology & Obstetrics, Emory University School of Medicine, Atlanta